On Oct 17, major Wall Street analysts update their ratings for $Johnson & Johnson (JNJ.US)$, with price targets ranging from $166 to $185.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and adjusts the target price from $169 to $175.
Citi analyst Joanne Wuensch maintains with a buy rating, and adjusts the target price from $180 to $185.
Wells Fargo analyst Larry Biegelsen maintains with a hold rating, and adjusts the target price from $163 to $166.
TD Cowen analyst Josh Jennings maintains with a buy rating, and maintains the target price at $185.
Furthermore, according to the comprehensive report, the opinions of $Johnson & Johnson (JNJ.US)$'s main analysts recently are as follows:
Johnson & Johnson's third-quarter results were largely in line with market expectations, thanks to the robust performance of its Innovative Medicine business, which helped to balance the challenges within the MedTech sector. Management's early commentary on the 2025 outlook conveyed a strong belief in achieving over $57 billion in sales from Innovative Medicine. The company's growth goals for MedTech between 2024 and 2027, aiming for the higher spectrum of 5%-7%, were noted, although this target is considered to be quite optimistic.
Following a third-quarter report which aligned with general expectations, the pharmaceutical segment surpassed forecasts while the medical technology division fell short. The company's outlook for 2025 remained largely in line with prior projections, leading to slight revisions in estimates.
Following Johnson & Johnson's third-quarter report, the company's movement towards resolving talc litigation and integrating several medical technology acquisitions, along with providing 'level-set 2025 commentary,' supports a positive perspective on the shares.
Johnson & Johnson's Q3 earnings exceeded expectations, reporting a 5.6% underlying growth excluding Covid-related contributions, which was primarily fueled by performance in Innovative Medicine, while MedTech experienced a lag, partly due to seasonal variations and challenges in the Asia Pacific region. Post-Q3 results indicate that the company is making significant operational strides, particularly with the advancement of its pipeline execution.
Johnson & Johnson's sales growth forecast for 2024 suggests a slowdown in growth during Q4, yet the management's remarks about 2025 appear promising for EPS expansion. Additionally, the company is of the view that substantial headway has been achieved in dealing with the talc litigation.
Here are the latest investment ratings and price targets for $Johnson & Johnson (JNJ.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月17日，多家華爾街大行更新了$強生 (JNJ.US)$的評級，目標價介於166美元至185美元。
摩根士丹利分析師Terence Flynn維持持有評級，並將目標價從169美元上調至175美元。
花旗分析師Joanne Wuensch維持買入評級，並將目標價從180美元上調至185美元。
富國集團分析師Larry Biegelsen維持持有評級，並將目標價從163美元上調至166美元。
TD Cowen分析師Josh Jennings維持買入評級，維持目標價185美元。
此外，綜合報道，$強生 (JNJ.US)$近期主要分析師觀點如下：
強生公司第三季度的業績基本符合市場預期，這要歸功於創新藥業務的強勁表現，有助於平衡醫療科技板塊的挑戰。管理層對2025年展望的早期評論表明對創新藥品銷售額超過570億美元的堅定信心。公司對2024年至2027年醫療科技業務的增長目標定在5%至7%的較高範圍，儘管這一目標被認爲相當樂觀。
在符合一般預期的第三季度報告之後，藥品領域超過了預測，而醫療技術部門則表現不佳。公司對2025年的展望與之前的預測基本一致，導致估計有輕微修訂。
在強生公司第三季度報告之後，公司朝着解決滑石訴訟、整合多項醫療科技收購以及提供'2025年平穩發展展望'的方向前進，支持股票正面觀點。
強生公司Q3收益超出預期，報告顯示，在不考慮與Covid相關貢獻的情況下，核心增長率爲5.6%，這主要得益於創新藥品的表現，而醫療技術則出現滯後，部分原因是由於季節變化和亞太地區的挑戰。Q3後的結果表明公司在運營方面取得了重要進展，特別是在推進其管線執行方面。
強生公司2024年的銷售增長預測表明在第四季度增長放緩，但管理層對2025年的評論看上去對EPS擴張前景樂觀。此外，公司認爲在處理滑石訴訟方面已經取得了實質性進展。
以下爲今日4位分析師對$強生 (JNJ.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
